相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1887
已完成
2
66.7%
招募中
1
33.3%
暂无批准数据
- PHASE Scientific has launched the world's largest clinical study for urine-based cervical cancer screening, enrolling 17,000 women in China to evaluate their proprietary PHASiFY™ technology. - The study sets three world records including the largest urine-based HPV screening trial and the first validation of urine-based methylation testing for cervical cancer detection. - PHASiFY™ technology achieves 93.42% sensitivity for high-risk HPV detection by concentrating HPV DNA in urine by more than 10,000 times. - The research addresses China's low screening coverage rate of 51.5% among women aged 35-64, well below WHO's 70% benchmark target.
- Trethera Corporation received two separate NIH SBIR grants totaling $5.3 million to advance TRE-515, a first-in-class deoxycytidine kinase inhibitor, for treating metastatic castration-resistant prostate cancer and systemic lupus erythematosus. - The $2.3 million grant will evaluate TRE-515 combined with radiation therapy in prostate cancer models, targeting a disease that claims 70% of patients within 5 years of diagnosis. - The $3 million grant will support advanced studies for lupus treatment, building on preclinical data showing TRE-515 can stop disease progression in mouse models. - TRE-515 works by inhibiting the nucleoside salvage pathway, depriving abnormal cells of DNA building blocks while maintaining a favorable safety profile in ongoing clinical trials.
- Piccolo Medical has received FDA 510(k) clearance for its second-generation SmartPICC Stylet and PM2+ System, marking a significant advancement in peripherally inserted central catheter placement technology. - The SmartPICC technology provides real-time bedside catheter tip confirmation using cardiac electrical activity, eliminating the need for confirmatory chest X-rays and reducing patient care delays. - The system incorporates proprietary ionic dilution technology for PICC navigation, offering clinicians real-time guidance during catheter insertion and immediate detection of improper vascular advancements. - Piccolo Medical has partnered with Spectrum Vascular as the exclusive North American distributor to commercialize this comprehensive vascular access solution.
- CanSino Biologics' Ad5-nCoV COVID-19 vaccine candidate is set to begin Phase 3 clinical trials in Pakistan in September 2020, marking the country's first Phase 3 vaccine trial. - The trial will recruit approximately 8,000 volunteers, primarily healthcare workers, across five major Pakistani cities over a four-month period with 12-month follow-up. - Despite Pakistan's COVID-19 cases dropping from over 6,000 daily in June to 426 on September 8, researchers believe adequate virus exposure remains for effective trial conduct. - The partnership between CanSino, Pakistan's National Institute of Health, and AJM Pharma aims to ensure preferential vaccine access and potential local manufacturing capabilities for Pakistan.
• St. Joseph's/Candler launches groundbreaking clinical trial across three locations to investigate optimized dosing strategies for CDK4/6 inhibitors in metastatic breast cancer treatment. • The study compares titrated dosing approach starting with lower doses versus standard dosing with reductions, aiming to enhance treatment outcomes and patient quality of life. • Led by Dr. Leonard Henry, the trial represents a significant advancement in local cancer care, making cutting-edge research accessible to patients in the Coastal Empire and Lowcountry regions.
- A randomized trial revealed that reconditioned pacemakers are as safe and effective as new ones after 90 days, suggesting a cost-effective alternative for low- and middle-income countries. - The FDA permits the export of re-sterilized pacemakers for reuse, even though the practice is prohibited in the U.S., highlighting potential global health implications. - An NIH-developed AI algorithm, TrialGPT, can efficiently match volunteers to clinical trials, summarizing eligibility criteria and potentially accelerating clinical research. - Despite known risks, Kratom remains widely available in U.S. tobacco and vape stores, with over two million Americans using it annually, raising concerns about deceptive marketing practices.
- Clene plans to submit a New Drug Application for CNM-Au8 in ALS under the accelerated approval pathway by the fourth quarter of 2025, following constructive FDA feedback on its statistical analysis plan. - The company will analyze neurofilament light biomarker data from its NIH-sponsored expanded access program in Q4 2025, intended to support the NfL changes previously demonstrated in the HEALEY ALS Platform Trial. - A second Type C meeting with the FDA is scheduled for Q3 2025 to review long-term survival benefits from CNM-Au8 30 mg treatment compared to controls from the HEALEY ALS Platform Trial. - For multiple sclerosis, Clene presented evidence of remyelination and neuronal repair with CNM-Au8 at the American Academy of Neurology meeting, showing improvements in cognition and visual function supported by advanced MRI and visual evoked potential assessments.
- Despite African Americans comprising 20% of multiple myeloma patients in the US, they represent only 6% of clinical trial participants, highlighting a significant disparity in medical research. - Analysis of 31 cancer drugs approved since 2015 reveals African American participation reached 10% in only two drug trials, demonstrating systemic underrepresentation in oncology research. - Major healthcare companies like Johnson & Johnson are implementing strategic shifts to increase diverse participation in clinical trials, while initiatives like NIH's All of Us program aim to deliver more inclusive precision medicine.
